350 related articles for article (PubMed ID: 27472034)
1. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous stem cell transplant: a cost-effectiveness analysis in Scotland.
Parker C; Woods B; Eaton J; Ma E; Selby R; Benson E; Engstrom A; Sajosi P; Briggs A; Bonthapally V
J Med Econ; 2017 Jan; 20(1):8-18. PubMed ID: 27472034
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of brentuximab vedotin for relapsed or refractory systemic anaplastic large-cell lymphoma in China.
Liu J; Zheng L; Chuang LH
J Med Econ; 2022; 25(1):99-107. PubMed ID: 34927526
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of brentuximab vedotin plus chemotherapy as frontline treatment of stage III or IV classical Hodgkin lymphoma.
Delea TE; Sharma A; Grossman A; Eichten C; Fenton K; Josephson N; Richhariya A; Moskowitz AJ
J Med Econ; 2019 Feb; 22(2):117-130. PubMed ID: 30375910
[TBL] [Abstract][Full Text] [Related]
4. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous transplant: meta-analysis versus historical data.
Bonthapally V; Wu E; Macalalad A; Yang H; Shonukan O; Liu Y; Chi A; Huebner D
Curr Med Res Opin; 2015 May; 31(5):993-1001. PubMed ID: 25772232
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation.
Hui L; von Keudell G; Wang R; Zeidan AM; Gore SD; Ma X; Davidoff AJ; Huntington SF
Cancer; 2017 Oct; 123(19):3763-3771. PubMed ID: 28640385
[TBL] [Abstract][Full Text] [Related]
6. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
Moskowitz CH; Nademanee A; Masszi T; Agura E; Holowiecki J; Abidi MH; Chen AI; Stiff P; Gianni AM; Carella A; Osmanov D; Bachanova V; Sweetenham J; Sureda A; Huebner D; Sievers EL; Chi A; Larsen EK; Hunder NN; Walewski J;
Lancet; 2015 May; 385(9980):1853-62. PubMed ID: 25796459
[TBL] [Abstract][Full Text] [Related]
7. Brentuximab vedotin compared with other therapies in relapsed/refractory Hodgkin lymphoma post autologous stem cell transplant: median overall survival meta-analysis.
Bonthapally V; Yang H; Ayyagari R; Tan RD; Cai S; Wu E; Gautam A; Chi A; Huebner D
Curr Med Res Opin; 2015; 31(7):1377-89. PubMed ID: 25950500
[TBL] [Abstract][Full Text] [Related]
8. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
[TBL] [Abstract][Full Text] [Related]
9. A Cost-effectiveness Analysis of Brentuximab Vedotin in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma.
Hux M; Zou D; Ma E; Sajosi P; Engstrom A; Selby R; Benson E; Briggs A; Bonthapally V
J Health Econ Outcomes Res; 2017; 4(2):188-203. PubMed ID: 37661948
[No Abstract] [Full Text] [Related]
10. Economic evaluation of brentuximab vedotin for persistent Hodgkin lymphoma.
Babashov V; Begen MA; Mangel J; Zaric GS
Curr Oncol; 2017 Feb; 24(1):e6-e14. PubMed ID: 28270727
[TBL] [Abstract][Full Text] [Related]
11. Brentuximab vedotin as salvage treatment in Hodgkin lymphoma naïve transplant patients or failing ASCT: the real life experience of Rete Ematologica Pugliese (REP).
Pavone V; Mele A; Carlino D; Specchia G; Gaudio F; Perrone T; Mazza P; Palazzo G; Guarini A; Loseto G; Eleonora P; Cascavilla N; Scalzulli P; Melpignano A; Quintana G; Di Renzo N; Tarantini G; Capalbo S
Ann Hematol; 2018 Oct; 97(10):1817-1824. PubMed ID: 30054707
[TBL] [Abstract][Full Text] [Related]
12. Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma.
Chen R; Palmer JM; Martin P; Tsai N; Kim Y; Chen BT; Popplewell L; Siddiqi T; Thomas SH; Mott M; Sahebi F; Armenian S; Leonard J; Nademanee A; Forman SJ
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2136-2140. PubMed ID: 26211987
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma.
Illidge T; Bouabdallah R; Chen R; Gopal AK; Moskowitz CH; Ramchandren R; Shustov AR; Tilly H; Trippett TM; Gibb A; Grove LE; Advani R
Leuk Lymphoma; 2015 Mar; 56(3):703-10. PubMed ID: 24913507
[TBL] [Abstract][Full Text] [Related]
14. [Brentuximab vedotin treatment in patients with relapsed or refractory Hodgkin lymphoma. A Hungarian retrospective study].
Molnár Z; Pinczés LI; Piukovics K; Istenes I; Wolf K; Csukly Z; Szomor Á; Illés Á; Miltényi Z
Orv Hetil; 2017 Oct; 158(41):1630-1634. PubMed ID: 29025292
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of pembrolizumab versus brentuximab vedotin for patients with relapsed or refractory classical Hodgkin's lymphoma: a United States payer perspective.
Large S; Hettle R; Balakumaran A; Wu E; Borse RH
J Med Econ; 2018 Nov; ():1-10. PubMed ID: 30303022
[TBL] [Abstract][Full Text] [Related]
16. Brentuximab vedotin consolidation post-autologous stem cell transplant in Hodgkin lymphoma patients at risk of residual disease: number needed to treat.
Gautam A; Zhu Y; Ma E; Lee SY; Zagadailov E; Teasell J; Richhariya A; Bonthapally V; Huebner D
Leuk Lymphoma; 2018 Jan; 59(1):69-76. PubMed ID: 28583027
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States.
Shah BD; Smith NJ; Feng C; Jeyakumar S; Castaigne JG; Faghmous I; Masouleh BK; Malone DC; Bishop MR
Adv Ther; 2022 Aug; 39(8):3678-3695. PubMed ID: 35727476
[TBL] [Abstract][Full Text] [Related]
18. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma.
Gopal AK; Chen R; Smith SE; Ansell SM; Rosenblatt JD; Savage KJ; Connors JM; Engert A; Larsen EK; Chi X; Sievers EL; Younes A
Blood; 2015 Feb; 125(8):1236-43. PubMed ID: 25533035
[TBL] [Abstract][Full Text] [Related]
19. Brentuximab vedotin in transplant-naive patients with relapsed or refractory hodgkin lymphoma: analysis of two phase I studies.
Forero-Torres A; Fanale M; Advani R; Bartlett NL; Rosenblatt JD; Kennedy DA; Younes A
Oncologist; 2012; 17(8):1073-80. PubMed ID: 22855426
[TBL] [Abstract][Full Text] [Related]
20. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma.
Chen R; Gopal AK; Smith SE; Ansell SM; Rosenblatt JD; Savage KJ; Connors JM; Engert A; Larsen EK; Huebner D; Fong A; Younes A
Blood; 2016 Sep; 128(12):1562-6. PubMed ID: 27432875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
